$81.39 Million in Sales Expected for Certara, Inc. (NASDAQ:CERT) This Quarter

Wall Street analysts forecast that Certara, Inc. (NASDAQ:CERT) will announce sales of $81.39 million for the current quarter, according to Zacks. Two analysts have made estimates for Certara’s earnings, with the highest sales estimate coming in at $83.18 million and the lowest estimate coming in at $79.60 million. Certara reported sales of $64.64 million during the same quarter last year, which would suggest a positive year over year growth rate of 25.9%. The company is scheduled to announce its next earnings results on Thursday, March 3rd.

According to Zacks, analysts expect that Certara will report full-year sales of $291.73 million for the current financial year, with estimates ranging from $290.30 million to $293.94 million. For the next year, analysts expect that the firm will report sales of $360.64 million, with estimates ranging from $357.55 million to $364.26 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that that provide coverage for Certara.

Certara (NASDAQ:CERT) last posted its earnings results on Monday, November 8th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. The company had revenue of $73.94 million for the quarter, compared to the consensus estimate of $73.90 million. Certara had a negative return on equity of 2.85% and a negative net margin of 21.07%.

Several equities research analysts have weighed in on the company. Zacks Investment Research upgraded Certara from a “sell” rating to a “hold” rating in a research note on Monday, November 15th. Robert W. Baird upped their target price on Certara from $32.00 to $41.00 and gave the stock an “outperform” rating in a research note on Friday, September 17th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $36.33.

NASDAQ CERT traded up $0.08 on Thursday, hitting $28.50. 737,420 shares of the company’s stock were exchanged, compared to its average volume of 733,283. The stock has a 50-day moving average of $36.64 and a 200-day moving average of $31.22. The company has a current ratio of 7.25, a quick ratio of 7.25 and a debt-to-equity ratio of 0.30. Certara has a 52 week low of $23.75 and a 52 week high of $45.48. The stock has a market cap of $4.55 billion and a price-to-earnings ratio of -67.86.

In other Certara news, major shareholder Avatar Parent L.P. Eqt sold 8,117,655 shares of the stock in a transaction dated Monday, November 22nd. The stock was sold at an average price of $29.74, for a total transaction of $241,419,059.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Justin Edge sold 9,000 shares of the stock in a transaction dated Monday, August 30th. The stock was sold at an average price of $33.50, for a total value of $301,500.00. Following the sale, the insider now owns 433,090 shares of the company’s stock, valued at $14,508,515. The disclosure for this sale can be found here. Insiders sold a total of 23,183,593 shares of company stock valued at $694,604,376 over the last quarter. 6.80% of the stock is owned by corporate insiders.

A number of institutional investors have recently modified their holdings of CERT. Citigroup Inc. grew its holdings in Certara by 131.2% during the 1st quarter. Citigroup Inc. now owns 4,926 shares of the company’s stock worth $134,000 after acquiring an additional 2,795 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Certara during the 1st quarter worth about $2,151,000. Stifel Financial Corp bought a new position in shares of Certara during the 1st quarter worth about $219,000. Nuveen Asset Management LLC bought a new position in shares of Certara during the 1st quarter worth about $3,504,000. Finally, Ameriprise Financial Inc. boosted its position in shares of Certara by 329.9% during the 1st quarter. Ameriprise Financial Inc. now owns 1,030,909 shares of the company’s stock worth $28,137,000 after purchasing an additional 791,099 shares in the last quarter. Hedge funds and other institutional investors own 48.87% of the company’s stock.

About Certara

Certara Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development.

Further Reading: Are Wall Street analysts’ stock ratings worth following?

Get a free copy of the Zacks research report on Certara (CERT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Certara (NASDAQ:CERT)

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.